112 related articles for article (PubMed ID: 21033251)
1. Mammalian target of rapamycin as a novel target in the treatment of hepatocellular carcinoma.
Guo Y; Liang X; Lu M; Weng T; Liu Y; Ye X
Hepatogastroenterology; 2010; 57(101):913-8. PubMed ID: 21033251
[TBL] [Abstract][Full Text] [Related]
2. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
3. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin regulates expression of β-catenin in hepatocellular carcinoma.
Feng Z; Fan X; Jiao Y; Ban K
Hum Pathol; 2011 May; 42(5):659-68. PubMed ID: 21239045
[TBL] [Abstract][Full Text] [Related]
5. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.
Evert M; Calvisi DF; Evert K; De Murtas V; Gasparetti G; Mattu S; Destefanis G; Ladu S; Zimmermann A; Delogu S; Thiel S; Thiele A; Ribback S; Dombrowski F
Hepatology; 2012 May; 55(5):1473-84. PubMed ID: 22271091
[TBL] [Abstract][Full Text] [Related]
6. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
7. Fructus ligustri lucidi extracts induce human glioma cell death through regulation of Akt/mTOR pathway in vitro and reduce glioma tumor growth in U87MG xenograft mouse model.
Jeong JC; Kim JW; Kwon CH; Kim TH; Kim YK
Phytother Res; 2011 Mar; 25(3):429-34. PubMed ID: 20737659
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T
Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
10. mTOR and P70 S6 kinase expression in primary liver neoplasms.
Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
[TBL] [Abstract][Full Text] [Related]
11. [Recombinant plasmid pEGFP-AFP-TK delivered by nano-magnetic fluids targeting killed AFP positive HepG2 cells in vitro].
Luo Y; Zhang YD; Peng J; Yan HX; Xue D; Wu K; Zhou L; Hang SW; Zhao JF
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 May; 25(5):437-9. PubMed ID: 19426602
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma.
Tam KH; Yang ZF; Lau CK; Lam CT; Pang RW; Poon RT
Cancer Lett; 2009 Jan; 273(2):201-9. PubMed ID: 18824293
[TBL] [Abstract][Full Text] [Related]
13. [Inhibitory effect of blocking expression of human augmenter of liver regeneration (hALR) on proliferation of hepatocellular carcinoma cell line HepG2].
Tang L; Sun H; Zhang L; Guo H; Zhang L; Liu Q
Ai Zheng; 2006 Jun; 25(6):671-6. PubMed ID: 16764759
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth.
Parent R; Kolippakkam D; Booth G; Beretta L
Cancer Res; 2007 May; 67(9):4337-45. PubMed ID: 17483347
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
16. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
Zakikhani M; Blouin MJ; Piura E; Pollak MN
Breast Cancer Res Treat; 2010 Aug; 123(1):271-9. PubMed ID: 20135346
[TBL] [Abstract][Full Text] [Related]
17. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis.
Tang C; Lu YH; Xie JH; Wang F; Zou JN; Yang JS; Xing YY; Xi T
Anticancer Drugs; 2009 Apr; 20(4):249-58. PubMed ID: 19174695
[TBL] [Abstract][Full Text] [Related]
19. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
20. Involvement of mTOR and survivin inhibition in tamoxifen-induced apoptosis in human hepatoblastoma cell line HepG2.
Guo R; Wang T; Shen H; Ge HM; Sun J; Huang ZH; Shu YQ
Biomed Pharmacother; 2010 Apr; 64(4):249-53. PubMed ID: 19931998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]